Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The firm's progenitor cell activation approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer,
Leer más
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The firm's progenitor cell activation approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.
Leer menos